Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13751Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Singhvi, Gautam | - |
| dc.date.accessioned | 2024-01-09T09:10:04Z | - |
| dc.date.available | 2024-01-09T09:10:04Z | - |
| dc.date.issued | 2021-07 | - |
| dc.identifier.uri | https://www.tandfonline.com/doi/full/10.1080/17425247.2021.1950686 | - |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13751 | - |
| dc.description.abstract | Rheumatoid arthritis (RA) is a chronic systemic inflammatory condition that mainly affects the lining of the synovial joints. It can progressively cause disability and even premature death. Moreover, it is associated with substantial socioeconomic burdens [Citation1]. Currently, RA affects more than 23 million people globally, including 12.6 million Indians [Citation1]. Recent findings have suggested the involvement of genetic factors in the development of RA. The HLA-DRB1 alleles that code shared epitopes (conserved sequence of amino acids in positions 70–74 of HLA-DRβ chains) are associated with the structural severity of RA. It was reported that more than 80% of the RA-affected individuals carry the HLA-DRB1*04 cluster, in which *04 signifies the allele group which corresponds to the serological type [Citation1] | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor & Francis | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | CD44 | en_US |
| dc.subject | Athritis therapy | en_US |
| dc.subject | Rheumatoid arthritis (RA) | en_US |
| dc.title | CD44 receptor-targeted novel drug delivery strategies for rheumatoid arthritis therapy | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Department of Pharmacy | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.